New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

(NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest individual-patient-data meta-analysis of Prolaris to date, ...
Nasdaq

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced the integration of Absolute Risk Reduction ...

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.
Nasdaq

Myriad announces its Prolaris test is still classified as ‘Advanced Tool’

Myriad Genetics (MYGN) announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network, NCCN, as an ‘Advanced Tool’ in the fight ...
Yahoo Finance

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
manilatimes

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, ...